Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × NSCLC × sintilimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 43 Stomach Neoplasms 35 Carcinoma, Non-Small-Cell Lung 27 Colorectal Neoplasms 17 Esophageal Squamous Cell Carcinoma 13 Nasopharyngeal Carcinoma 10 Lung Neoplasms 10 Rectal Neoplasms 8 Pancreatic Neoplasms 7 Esophageal Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 5 Liver Neoplasms 5 Cholangiocarcinoma 5 Neoplasms 4 Triple Negative Breast Neoplasms 3 Recurrence 3 Lymphoma, Extranodal NK-T-Cell 3 Colorectal Cancer Metastatic 3 Carcinoma, Renal Cell 3 Breast Neoplasms 3 Uterine Cervical Neoplasms 2 Turcot syndrome 2 Thyroid Neoplasms 2 Small Cell Lung Carcinoma 2 Sarcoma 2 Nonsquamous Non-Small Cell Lung Cancer 2 Neuroendocrine Tumors 2 Neoplasm Metastasis 2 Locally Advanced Rectal Cancer 2 Glioblastoma 2

Interventions

Drug Therapy 8 osimertinib 7 Pemetrexed 7 Radiotherapy 6 anlotinib 5 Carboplatin 5 Radiosurgery 4 Gefitinib 4 Docetaxel 4 tislelizumab 3 pembrolizumab 3 icotinib 3 aflutinib 3 Vinorelbine 3 Gemcitabine 3 Erlotinib Hydrochloride 3 Cisplatin 3 toripalimab 2 dacomitinib 2 apatinib 2 Tyrosine Kinase Inhibitors 2 Thalidomide 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Platinum 2 Paclitaxel 2 Immune Checkpoint Inhibitors 2 Chemotherapy, Adjuvant 2 Chemoradiotherapy 2 Bevacizumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06479759 2024-06-28

ACCLAIM

Shanghai Pulmonary Hospital, Shanghai, China

Phase 2 Recruiting

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡